Elusys Therapeutics has published data from five clinical trials of ANTHIM, which was used to support the marketing approval by the U.S. Food and Drug Administration.
Read More »
PERRIGO COMPANY PLC: Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%
IONIS PHARMACEUTICALS INC.: Licences New Antisense Drug for Kidney Disease to AstraZeneca
MYLAN INC.: Receives Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program
PHIZER: Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
TEVA PHARMACEUTICAL INDUSTRIES LTD.: Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol